Drug intelligence / Profile preview

NWL-CSCs

Development stage: Preclinical
Lead developer: New World Laboratories
Modality: Stem Cell Therapies → Cell Therapies

Overview

NWL-CSCs (Cardiac Stem-like Cells) is a personalized, autologous cell therapy being developed by New World Laboratories for cardiac regeneration and the treatment of cardiovascular indications. The therapy consists of cardiac stem-like cells generated from a patient's own somatic cells (such as skin or blood cells) through a proprietary direct reprogramming process. This method does not involve genetic engineering, distinguishing it from traditional induced pluripotent stem cell (iPSC) approaches. The mechanism of action involves the repair or regeneration of damaged cardiac tissue. NWL-CSCs is currently in the preclinical stage of development as part of a broader pipeline of personalized stem cell technologies.

Other names: Cardiac Stem-like Cells

Beyond the preview

Go deeper on NWL-CSCs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWL-CSCs.

Explore the full profile